Daiichi-Sankyo Austria GmbH

What Daiichi-Sankyo Austria GmbH does

Daiichi-Sankyo Austria GmbH is the Austrian operating subsidiary of Daiichi Sankyo Europe GmbH, itself part of the Japan-headquartered Daiichi Sankyo pharmaceutical group. The entity is registered as a Gesellschaft mit beschränkter Haftung (GmbH) at Euro Plaza, Kranichberggasse 4, 1120 Vienna, under FN 106405d, and is led by Managing Director Mag. (FH) Elisabeth Keil with Prokuristen Markus Krammer and Eric Rymarz. The company operates as a pharmaceutical wholesale distributor (Großhandel mit Arzneimitteln) under the Austrian Arzneimittelgesetz (AMG), selling prescription cardiovascular and oncology products exclusively to authorized buyers (pharmacies and hospitals) in Austria, and is supervised by the Medizinmarktaufsicht / Bundesamt für Sicherheit im Gesundheitswesen (BASG).

Its commercial surface combines regulated wholesale distribution of Daiichi Sankyo's cardiology and oncology portfolio — including the ADC oncology brands ENHERTU® and VANFLYTA® — with HCP-focused medical-education programs such as DS-Akademie, Cardiologists of Tomorrow, and We Care for Every Heartbeat, plus restricted information portals gated by DocCheck authentication. Beyond distribution, the Austrian entity hosts elements of the parent group's European R&D footprint through the DSPACE research platform, the European Pipeline disclosures, and the Translational Research Center Europe. Revenue is generated via regulated unit-priced wholesale sales (AEP-based) billed monthly on 30-day net terms, with cash discounts of 1.0-1.5% for early payment. No independent funding rounds, M&A, or public listing exist; the company is wholly owned by Daiichi Sankyo Europe GmbH and operates within the DACH/Austria single-country scope.

Name

Daiichi-Sankyo Austria GmbH

Legal name

Daiichi Sankyo Austria GmbH

Website

https://daiichi-sankyo.at

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Daiichi-Sankyo Austria GmbH is the Vienna-based Austrian wholesale and medical-affairs subsidiary of Japan's Daiichi Sankyo Group, distributing prescription cardiovascular and oncology (ADC) products to pharmacies and hospitals under Austrian AMG regulations.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Cardiology and Oncology)

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Prescription pharmaceuticals
• Cardiology medications
• Oncology therapeutics
• Antibody-drug conjugates
• Pharmaceutical wholesale distribution

Headquarters

HQ city

Vienna (Wien)

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Wholesale Distribution: The company operates as a pharmaceutical wholesale distributor (Großhandel mit Arzneimitteln) selling prescription medications to pharmacies and hospitals. Revenue is generated through product sales of cardiovascular and oncology pharmaceuticals.
2. Pharmaceutical Product Sales: Direct sales of pharmaceutical preparations to authorized buyers including pharmacies and medical institutions, governed by Austrian pharmaceutical law (AMG) and relevant regulations.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Daiichi-Sankyo Austria GmbH operates as a pharmaceutical wholesale distributor (Großhandel mit Arzneimitteln) selling prescription Daiichi Sankyo products — primarily cardiovascular and oncology medications — to authorized buyers including pharmacies and hospitals in Austria. The entity also supports the group's European research and development activities through the Austrian base and provides healthcare-professional education and training resources.

Product overview

Daiichi-Sankyo Austria GmbH is the Austrian subsidiary of the global Japanese pharmaceutical company Daiichi Sankyo. The company operates as a pharmaceutical wholesale distributor and research/development hub in Europe. Their product portfolio includes prescription oncology medications (ENHERTU® and VANFLYTA®) and cardiovascular therapies. They support healthcare professionals through educational initiatives including DS-Akademie and Cardiologists of Tomorrow, and maintain active research operations through their Pipeline and DSPACE research platforms, as well as a Translational Research Center Europe. The company also provides patient information resources and operates a non-public area for healthcare professionals accessible via DocCheck authentication.

Differentiator

Problem solved

Functional benefit

Products and services

• ENHERTU® A prescription Daiichi Sankyo oncology medication (an antibody-drug conjugate) distributed in Austria to authorized healthcare providers, with training materials provided for healthcare professionals per its Risk Management Plan.
• VANFLYTA® A prescription Daiichi Sankyo oncology medication distributed in Austria to authorized healthcare providers, with training materials provided for healthcare professionals per its Risk Management Plan.
• Cardiovascular prescription pharmaceuticals Daiichi Sankyo cardiovascular prescription medicines (covering conditions such as atherosclerosis and other heart-and-circulatory diseases) wholesale-distributed to authorized pharmacies and hospitals in Austria.
• DS-Akademie (medical education service for cardiology) An academic-style educational service for healthcare professionals, providing cardiology training and educational resources to support safe and effective prescribing of Daiichi Sankyo cardiovascular products.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature2 records

Partnerships

Six partnerships are on record, tiered core and minor.

• DocCheck Medical Services GmbHcoreTechnology or IntegrationDocCheck provides healthcare professional authentication and login services for the restricted website area. HCPs must authenticate via DocCheck to access prescription medication information. This is required for regulatory compliance to ensure only medical professionals access prescription drug information.
• Wirtschaftskammer ÖsterreichminorOthersChamber of Commerce membership for Austrian businesses
• PHARMIG - Verband der pharmazeutischen Industrie ÖsterreichsminorOthersAustrian pharmaceutical industry association membership
• FOPI - Forum der forschenden pharmazeutischen IndustrieminorOthersAustrian forum for research-based pharmaceutical industry
• J-Pharm - Japanische Pharma-Industrie in ÖsterreichminorOthersJapanese pharmaceutical industry association in Austria
• Daiichi Sankyo Europe GmbHcoreOthersParent company (Gesellschafter/shareholder) of Daiichi Sankyo Austria GmbH. Located in Munich, Germany. Coordinates European operations including pharmacovigilance data processing.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Takeda Pharma Ges.m.b.H. (Austria): Austrian affiliate of Takeda with oncology and specialty-care presence. Comparable as a Japan-headquartered global pharma operating a regulated Austrian wholesale and HCP-engagement model.
• Merck GmbH (Austria): Austrian subsidiary of Merck, distributing specialty pharmaceuticals (notably oncology) through Austrian wholesale channels. Comparable therapeutic focus, regulatory setup, and B2B distribution model.
• Pfizer Corporation Austria GmbH: Austrian affiliate of Pfizer, distributing a broad branded pharmaceutical portfolio including cardiovascular products through Austrian wholesalers to pharmacies and hospitals. Same regulatory framework under AMG and BASG.
• Roche Austria GmbH: Austrian subsidiary of Roche, a global leader in oncology pharmaceuticals. Comparable as a wholesale-licensed distributor of high-value specialty oncology medicines into the same hospital and pharmacy channels in Austria.
• Bayer Austria Gesellschaft mbH: Austrian subsidiary of Bayer, with strong branded cardiovascular and specialty pharma presence distributed via Austrian wholesale channels. Highly comparable therapy-area overlap and go-to-market model.
• AstraZeneca Austria GmbH: Country subsidiary of AstraZeneca with a comparable Austrian footprint in oncology and cardiovascular specialty pharmaceuticals. Same go-to-market: HCP-facing sales, restricted medical-professional content, and wholesale distribution to pharmacies and hospitals.
• Novartis Pharma GmbH (Austria): Austrian operating subsidiary of Novartis, a global pharma major with overlapping branded pharmaceutical portfolios in cardiology and oncology. Directly comparable in business model: wholesale-distributed prescription medicines, hospital/pharmacy channel, HCP-targeted education, and pipeline-driven launches in Austria.
• Sanofi-Aventis GmbH (Austria): Austrian subsidiary of Sanofi distributing branded prescription medicines (notably in cardiology and specialty care) via licensed wholesale to pharmacies and hospitals under Austrian AMG.
• Boehringer Ingelheim RCV GmbH & Co KG (Austria): Austrian operating unit of Boehringer Ingelheim, focused on cardiometabolic and respiratory specialty pharmaceuticals. Direct competitor in the cardiovascular therapy area and operates the same wholesale-to-pharmacy/hospital distribution model.

Others

• PHARMIG – Verband der pharmazeutischen Industrie Österreichs: Austrian pharmaceutical industry association of which Daiichi Sankyo Austria is a member. Not a competitor but a relevant ecosystem counterpart: defines industry standards, advocates on pricing/reimbursement policy, and shapes the regulatory environment in which all of the above peers operate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/daiichi-sankyo-austria-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daiichi-Sankyo Austria GmbH